MBX

MBX Biosciences, Inc.

Latest Form 4:Sale$24KbyAzoulay Salomon (Chief Medical Officer) · filed Aug 5, 2026

MBX Biosciences, Inc. (MBX) has 16 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Aug 5, 2026.

The most active filer is Chief Medical Officer Azoulay Salomon with 3 filings. Insiders have net sold $2.2M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Peter Kent Hawryluk
  • Employees:43
  • HQ:Carmel, IN, US
  • IPO:2000-01-14

Insider Buying

$13.1M

reported purchases (SEC code P)

Insider Selling

$2.7M

reported sales (SEC code S)

Unique Insiders

4

in the rolling window

Market Cap

$3.2B

latest known value

Source
Sale$24KAug 5SEC ↗
Sale$2.7MMay 11SEC ↗
Sale$18KMay 8SEC ↗
Azoulay SalomonFirst filing
Sale$7KMay 8SEC ↗
Hawryluk P. KentFirst in 5 months
Purchase$526KMar 16SEC ↗
Hawryluk P. KentFirst filing
Purchase$273KOct 21SEC ↗
Hoerter Steven L.First filing
Purchase$265KOct 20SEC ↗
Heron Patrick JFirst filing
Purchase$12.0MSep 30SEC ↗

Related companies

MBX Biosciences, Inc. is in the Healthcare sector.